Middleton & Co. Inc. MA Has $7.14 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Middleton & Co. Inc. MA lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,307 shares of the company’s stock after buying an additional 695 shares during the quarter. Middleton & Co. Inc. MA’s holdings in IDEXX Laboratories were worth $7,137,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of IDXX. Private Trust Co. NA boosted its holdings in IDEXX Laboratories by 21.2% during the first quarter. Private Trust Co. NA now owns 240 shares of the company’s stock valued at $101,000 after acquiring an additional 42 shares during the period. D.A. Davidson & CO. increased its holdings in shares of IDEXX Laboratories by 7.5% during the 1st quarter. D.A. Davidson & CO. now owns 1,800 shares of the company’s stock worth $756,000 after purchasing an additional 126 shares during the period. OneDigital Investment Advisors LLC raised its holdings in IDEXX Laboratories by 32.1% in the 1st quarter. OneDigital Investment Advisors LLC now owns 744 shares of the company’s stock valued at $312,000 after acquiring an additional 181 shares in the last quarter. Concurrent Investment Advisors LLC raised its stake in shares of IDEXX Laboratories by 59.1% in the first quarter. Concurrent Investment Advisors LLC now owns 1,370 shares of the company’s stock valued at $575,000 after purchasing an additional 509 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in IDEXX Laboratories by 8.2% during the first quarter. Envestnet Asset Management Inc. now owns 161,829 shares of the company’s stock worth $67,960,000 after buying an additional 12,255 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Michael G. Erickson sold 406 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the transaction, the executive vice president directly owned 11,287 shares in the company, valued at $7,336,098.52. This trade represents a 3.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Nimrata Hunt sold 1,200 shares of the company’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $656.53, for a total value of $787,836.00. Following the completion of the sale, the executive vice president directly owned 16,807 shares of the company’s stock, valued at approximately $11,034,299.71. This trade represents a 6.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 9,243 shares of company stock worth $6,018,650. Company insiders own 0.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IDXX. Piper Sandler reissued a “neutral” rating and issued a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a research report on Monday. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Sunday, September 28th. BTIG Research increased their price target on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $730.50.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $720.21 on Thursday. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $735.00. The stock has a market capitalization of $57.62 billion, a P/E ratio of 59.97, a P/E/G ratio of 4.06 and a beta of 1.62. The business has a 50-day moving average price of $642.72 and a two-hundred day moving average price of $575.17.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, November 3rd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.14 by $0.26. The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. IDEXX Laboratories’s revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.